{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-020984","form_type":"8-K","ticker":"GOVX","cik":"0000832489","company_name":"GeoVax Labs, Inc.","filed_at":"2026-06-17T20:32:58+00:00","discovered_at":"2026-06-17T20:34:00.428694+00:00","generated_at":"2026-06-17T20:35:17.283719+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.15,"confidence":"high","headline":"GeoVax shareholders approve all proposals, including three warrant exercises for up to 3.84M shares","bullets":["All seven director nominees (Chase, Dodd, Kollintzas, Lemerond, McNally, Morgan, Spencer) elected with >417K votes each.","Warrant exercise approvals: Feb 2026 (865,804 shares), Mar 2026 (1,269,316 shares), May 2026 (1,702,986 shares).","Ratification of Wipfli LLP as auditor for FY2026 passed with 1,185,525 votes for.","Advisory vote on executive compensation approved (385,843 for); stockholders chose a three-year frequency for future say-on-pay votes."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-020984","json":"https://secwatch.observer/filing/0001437749-26-020984.json","markdown":"https://secwatch.observer/filing/0001437749-26-020984.md","text":"https://secwatch.observer/filing/0001437749-26-020984.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/832489/000143774926020984/0001437749-26-020984-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/832489/000143774926020984/govx20260617_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T20:35:17.283719+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"18ecbe8be2c198772ec995516f1bd29623323ed0","claim":"GeoVax Labs, Inc. shareholders approved Advisory Vote on the Compensation of our Named Executive Officers at the 2026-06-17 meeting.","evidence_excerpt":"Advisory Vote on the Compensation of our Named Executive Officers Our stockholders approved, on an advisory basis, the compensation of our Named Executive Officers (as defined in the Proxy Statement). There were a total of 810,066 broker non-votes on this item. For Against Abstain 385,843 65,826 26,949","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/832489/000143774926020984/0001437749-26-020984-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-17"}],"fact_type":"shareholder_vote"},{"claim_id":"2e0635234c8f2194c13aa657383ecc981e5f8717","claim":"GeoVax Labs, Inc. shareholders approved Approval of the March 2026 Warrant Exercise Proposal at the 2026-06-17 meeting.","evidence_excerpt":"Approval of the March 2026 Warrant Exercise Proposal Our stockholders approved a proposal to approve, pursuant to Nasdaq listing rules, the issuance of up to 1,269,316 shares of our common stock upon exercise of common stock purchase warrants issued to certain institutional investors in connect with the warrant exercise inducement which occurred on March 31, 2026. There were a total of 810,066 broker non-votes on this item. For Against Abstain 395,365 66,838 16,415","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/832489/000143774926020984/0001437749-26-020984-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-17"}],"fact_type":"shareholder_vote"},{"claim_id":"4538b2f335333a910575e2cccb5b0a701aae4813","claim":"GeoVax Labs, Inc. shareholders approved Election of Directors at the 2026-06-17 meeting.","evidence_excerpt":"Election of Directors Our stockholders voted to elect the slate of directors consisting of seven members to hold office until the next annual meeting of stockholders or until their successors are duly elected and qualified. There were a total of 810,066 broker non-votes on this item. Nominee ​ For ​ ​ Withheld ​ Randal D. Chase ​ ​ 420,305 ​ ​ ​ 58,313 ​ David A. Dodd ​ ​ 418,963 ​ ​ ​ 59,655 ​ Dean G. Kollintzas ​ ​ 420,198 ​ ​ ​ 58,420 ​ Nicole Lemerond ​ ​ 417,920 ​ ​ ​ 61,426 ​ Robert T. McNally ​ ​ 419,481 ​ ​ ​ 59,137 ​ Jayne Morgan ​ ​ 420,422 ​ ​ ​ 58,196 ​ John N. Spencer, Jr. ​ ​ 420,434 ​ ​ ​ 58,184 ​","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/832489/000143774926020984/0001437749-26-020984-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-17"}],"fact_type":"shareholder_vote"},{"claim_id":"50171f6bd01bde4f3a8d7d8b354a6046172b8637","claim":"GeoVax Labs, Inc. shareholders approved Approval of the May 2026 Warrant Exercise Proposal at the 2026-06-17 meeting.","evidence_excerpt":"Approval of the May 2026 Warrant Exercise Proposal Our stockholders approved a proposal to approve, pursuant to Nasdaq listing rules, the issuance of up to 1,702,986 shares of our common stock upon exercise of common stock purchase warrants issued to certain institutional investors in connect with the warrant exercise inducement which occurred on May 7, 2026. There were a total of 810,066 broker non-votes on this item. For Against Abstain 375,831 35,336 67,451","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/832489/000143774926020984/0001437749-26-020984-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-17"}],"fact_type":"shareholder_vote"},{"claim_id":"5c1cf82df216949ec891295901beb36a176b5c77","claim":"GeoVax Labs, Inc. shareholders approved Approval of the February 2026 Warrant Exercise Proposal at the 2026-06-17 meeting.","evidence_excerpt":"Approval of the February 2026 Warrant Exercise Proposal Our stockholders approved a proposal to approve, pursuant to Nasdaq listing rules, the issuance of up to 865,804 shares of our common stock upon exercise of common stock purchase warrants issued to certain institutional investors in connect with the private placement offering which occurred on February 17, 2026. There were a total of 810,066 broker non-votes on this item. For Against Abstain 395,198 65,103 18,317","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/832489/000143774926020984/0001437749-26-020984-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-17"}],"fact_type":"shareholder_vote"},{"claim_id":"a5f3121ed5d4d1e70ac01ccbf4385743f268a8e5","claim":"GeoVax Labs, Inc. shareholders approved Ratification of Independent Auditor at the 2026-06-17 meeting.","evidence_excerpt":"Ratification of Independent Auditor Our stockholders approved the ratification of Wipfli LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. There were no broker non-votes on this item. For Against Abstain 1,185,525 37,409 65,750","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/832489/000143774926020984/0001437749-26-020984-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-17"}],"fact_type":"shareholder_vote"},{"claim_id":"e7d51112011f9efa8d3274f713e171e432a8c8d4","claim":"GeoVax Labs, Inc. shareholders approved Advisory Vote on the Frequency of Future Advisory Votes on the Compensation of our Named Executive Officers at the 2026-06-17 meeting.","evidence_excerpt":"Advisory Vote on the Frequency of Future Advisory Votes on the Compensation of our Named Executive Officers Our stockholders approved, on an advisory basis, the frequency of future advisory votes on the compensation of our Named Executive Officers (as defined in the Proxy Statement). The determination was to hold such advisory votes on a three-year cycle. 1 Year 2 Years 3 Years Abstain 339,064 24,463 97,058 18,033","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/832489/000143774926020984/0001437749-26-020984-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay frequency"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-17"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}